Protagonist Therapeutics (PTGX)

Protagonist Therapeutics (PTGX) Stock Price & Analysis


PTGX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$6.91 - $25.76
Previous Close$22.34
Average Volume (3M)1.67M
Market Cap
Enterprise Value$911.79M
Total Cash (Recent Filing)$237.35M
Total Debt (Recent Filing)$3.66M
Price to Earnings (P/E)-8.6
May 10, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.60
Shares Outstanding51,275,166
10 Day Avg. Volume1,297,930
30 Day Avg. Volume1,667,111
Standard Deviation0.30
Financial Highlights & Ratios
Price to Book (P/B)4.93
Price to Sales (P/S)40.55
Price to Cash Flow (P/CF)39.50
P/FCF Ratio-9.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue34.30
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-7.35
Price Target Upside54.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Protagonist Therapeutics’s price range in the past 12 months?
Protagonist Therapeutics lowest stock price was $6.91 and its highest was $25.76 in the past 12 months.
    What is Protagonist Therapeutics’s market cap?
    Currently, no data Available
    When is Protagonist Therapeutics’s upcoming earnings report date?
    Protagonist Therapeutics’s upcoming earnings report date is May 10, 2023 which is in 41 days.
      How were Protagonist Therapeutics’s earnings last quarter?
      Protagonist Therapeutics released its earnings results on Mar 15, 2023. The company reported -$0.69 earnings per share for the quarter, missing the consensus estimate of -$0.668 by -$0.022.
        Is Protagonist Therapeutics overvalued?
        According to Wall Street analysts Protagonist Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Protagonist Therapeutics pay dividends?
          Protagonist Therapeutics does not currently pay dividends.
          What is Protagonist Therapeutics’s EPS estimate?
          Protagonist Therapeutics’s EPS estimate is -$0.73.
            How many shares outstanding does Protagonist Therapeutics have?
            Protagonist Therapeutics has 51,275,166 shares outstanding.
              What happened to Protagonist Therapeutics’s price movement after its last earnings report?
              Protagonist Therapeutics reported an EPS of -$0.69 in its last earnings report, missing expectations of -$0.668. Following the earnings report the stock price went down -3.742%.
                Which hedge fund is a major shareholder of Protagonist Therapeutics?
                Among the largest hedge funds holding Protagonist Therapeutics’s share is Farallon Capital Management, L.L.C.. It holds Protagonist Therapeutics’s shares valued at 40M.


                  Protagonist Therapeutics Stock Smart Score

                  The Protagonist Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Protagonist Therapeutics

                  Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. The firm's initial lead product candidates, PTG-100 and PTG-200, are being developed for moderate-to-severe ulcerative colitis and Crohn's disease, respectively. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.


                  Top 5 ETFs holding PTGX

                  Market Value
                  Smart Score
                  Dimensional U.S. Equity ETF
                  Up to five ETFs with an Outperform Smart Score that hold PTGX. The ETFs are listed according to market value of PTGX within the ETF


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  C4 Therapeutics
                  Lexicon Pharmaceuticals
                  Poseida Therapeutics
                  Arbutus Biopharma
                  Kodiak Sciences

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis